Fumihiro Kawai

Fumihiro Kawai

Auto-generated profile, based on publicly available information

Fumihiro Kawai

Yokohama City University, Suehiro 1-7-29, Tsurumi, Yokohama 230-0045, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2008 in Nature
Verified
Journal Article
Closed access
PDF file
EOEiji Obayashi
Eiji Obayashi
HYHisashi Yoshida
Hisashi Yoshida
FKFumihiro Kawai
Fumihiro Kawai
NSNaoya Shibayama
Naoya Shibayama
AKAtsushi Kawaguchi
Atsushi Kawaguchi
SPSam-Yong Park
Sam-Yong Park

1 April 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
SSSatomi Shimura
Satomi Shimura
Koichi WatashiKoichi Watashi
Koichi Watashi
KFKento Fukano
Kento Fukano
MPMichael Peel
Michael Peel
ASAnn Sluder
Ann Sluder
TWTakaji Wakita
Takaji Wakita

24 February 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASAyana Sato-Tomita
Ayana Sato-Tomita
TSTokushi Sato
Tokushi Sato
KIKouhei Ichiyanagi
Kouhei Ichiyanagi
SNShunsuke Nozawa
Shunsuke Nozawa
HIHirohiko Ichikawa
Hirohiko Ichikawa
SAShin-Ichi Adachi
Shin-Ichi Adachi
Proteins harbor a number of cavities of relatively small volume. Although these packing defects are associated with the thermodynamic instability of the proteins, the cavities also play specific roles in controlling protein functions, e.g., ligand migration and binding. This issue has been extensively studied in a well-known protein, myoglobin (Mb). Mb reversibly binds gas ligands at the heme site buried in the protein matrix and possesses several internal cavities in which ligand molecules can reside. It is still an open question as to how a ligand finds its migration pathways between the internal cavities. Here, we report on the dynamic and sequential structural deformation of internal cavities during the ligand migration process in Mb. Our method, the continuous illumination of native carbonmonoxy Mb crystals with pulsed laser at cryogenic temperatures, has revealed that the migration of the CO molecule into each cavity induces structural changes of the amino acid residues around the cavity, which results in the expansion of the cavity with a breathing motion. The sequential motion of the ligand and the cavity suggests a self-opening mechanism of the ligand migration channel arising by induced fit, which is further supported by computational geometry analysis by the Delaunay tessellation method. This result suggests a crucial role of the breathing motion of internal cavities as a general mechanism of ligand migration in a protein matrix.

1 December 2015 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
MKManabu Kaneko
Manabu Kaneko
Koichi WatashiKoichi Watashi
Koichi Watashi
SKShinji Kamisuki
Shinji Kamisuki
HMHiroki Matsunaga
Hiroki Matsunaga
MIMasashi Iwamoto
Masashi Iwamoto
TWTakaji Wakita
Takaji Wakita
Anti-hepatitis B virus (HBV) drugs are currently limited to nucleos(t)ide analogs (NAs) and interferons. A challenge of drug development is the identification of small molecules that suppress HBV infection from new chemical sources. Here, from a fungus-derived secondary metabolite library, we identify a structurally novel tricyclic polyketide, named vanitaracin A, which specifically inhibits HBV infection. Vanitaracin A inhibited the viral entry process with a submicromolar 50% inhibitory concentration (IC 50 ) (IC 50 = 0.61 ± 0.23 μM), without evident cytotoxicity (50% cytotoxic concentration of >256 μM; selectivity index value of >419) in primary human hepatocytes. Vanitaracin A did not affect the HBV replication process. This compound was found to directly interact with the HBV entry receptor sodium taurocholate cotransporting polypeptide (NTCP) and impaired its bile acid transport activity. Consistent with this NTCP targeting, antiviral activity of vanitaracin A was observed with hepatitis D virus (HDV) but not hepatitis C virus. Importantly, vanitaracin A inhibited infection by all HBV genotypes tested (genotypes A to D) and clinically relevant NA-resistant HBV isolate. Thus, we identified a fungal metabolite, vanitaracin A, which was a potent, well-tolerated, and broadly active inhibitor of HBV and HDV entry. This compound, or its related analogs, could be part of an antiviral strategy for preventing reinfection with HBV, including clinically relevant nucleos(t)ide analog-resistant virus. IMPORTANCE For achieving better treatment and prevention of hepatitis B virus (HBV) infection, anti-HBV agents targeting a new molecule are in great demand. Although sodium taurocholate cotransporting polypeptide (NTCP) has recently been reported to be an essential host factor for HBV entry, there is a limited number of reports that identify new compounds targeting NTCP and inhibiting HBV entry. Here, from an uncharacterized chemical library, we isolated a structurally new compound, named vanitaracin A, which inhibited the process of entry of HBV and hepatitis D virus (HDV). This compound was suggested to directly interact with NTCP and inhibit its transporter activity. Importantly, vanitaracin A inhibited the entry of all HBV genotypes examined and of a clinically relevant nucleos(t)ide analog-resistant HBV isolate.

1 October 2012 in Journal of Molecular Biology
Verified
Journal Article
Closed access
HYHisashi Yoshida
Hisashi Yoshida
FKFumihiro Kawai
Fumihiro Kawai
EOEiji Obayashi
Eiji Obayashi
SASatoko Akashi
Satoko Akashi
DRDavid Roper
David Roper
SPSam-Yong Park
Sam-Yong Park

31 May 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MOMio Ohki
Mio Ohki
KSKanako Sugiyama
Kanako Sugiyama
FKFumihiro Kawai
Fumihiro Kawai
HTHitomi Tanaka
Hitomi Tanaka
YNYuuki Nihei
Yuuki Nihei
SPSam-Yong Park
Sam-Yong Park
Significance: Optogenetics is a rapidly growing field in which light is used to control biological systems. We show that Oscillatoria acuminata photoactivated adenylate cyclase (OaPAC) protein produces the fundamental second messenger cyclic-AMP (cAMP) in response to blue light, is stable and functional in different mammalian cell types, and can be used to trigger events by raising cAMP level. OaPAC consists of a catalytic domain controlled by a photosensitive blue light using flavin (BLUF) domain. We have solved the crystal structure to show how activity is triggered by light, and guide mutagenesis experiments. Although the catalytic domain resembles known cyclases, the BLUF domains form an unusual intertwined structure. The protein activity is the same in solution as in the crystal, showing that the activation mechanism involves only small molecular movements.